Translational Neurogenomics Laboratory, Mental Health and Neuroscience, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Department of Psychiatry, Amsterdam UMC, location University of Amsterdam, Amsterdam, the Netherlands.
Mol Psychiatry. 2024 Nov;29(11):3694-3705. doi: 10.1038/s41380-024-02547-z. Epub 2024 May 29.
Substance use disorders represent a significant public health concern with considerable socioeconomic implications worldwide. Twin and family-based studies have long established a heritable component underlying these disorders. In recent years, genome-wide association studies of large, broadly phenotyped samples have identified regions of the genome that harbour genetic risk variants associated with substance use disorders. These regions have enabled the discovery of putative causal genes and improved our understanding of genetic relationships among substance use disorders and other traits. Furthermore, the integration of these data with clinical information has yielded promising insights into how individuals respond to medications, allowing for the development of personalized treatment approaches based on an individual's genetic profile. This review article provides an overview of recent advances in the genetics of substance use disorders and demonstrates how genetic data may be used to reduce the burden of disease and improve public health outcomes.
物质使用障碍是一个重大的公共卫生关注点,在全球范围内具有相当大的社会经济影响。双胞胎和基于家庭的研究长期以来确立了这些障碍的遗传组成部分。近年来,对广泛表型样本的全基因组关联研究已经确定了基因组中与物质使用障碍相关的遗传风险变异体所在的区域。这些区域使我们能够发现潜在的因果基因,并增进我们对物质使用障碍和其他特征之间遗传关系的理解。此外,将这些数据与临床信息相结合,为我们了解个体对药物的反应提供了有希望的见解,从而可以根据个体的遗传特征制定个性化的治疗方法。本文综述了物质使用障碍遗传学的最新进展,并展示了如何利用遗传数据来减轻疾病负担和改善公共卫生结果。